The external validation cohort of 101 NSCLC patients undergoing ICI therapy was similar to the primary dataset (Graz cohort) in terms of the CRP distribution (median CRP: 32 mg/mL (25th–75th percentile: 11–64), follow-up interval (median: 19.1 months (12.0–26.7)) and several other baseline covariables (Table S5). This evidence concerns the gene CRP and non-small cell lung carcinoma.